LCT is a global leader in developing cell transplant therapies to treat chronic disease and NTCELL is LCT's lead product for treatment of neurodegenerative disorders. NTCELL has been developed using LCT's pioneering animal-cell-based transplantation and encapsulation platform.

The pre-clinical studies were performed in animals in which a Parkinson's-like condition had been induced. In all of the studies, transplantation of NTCELL into the affected brain regions reduced movement disorders and neurological defects associated with the disease compared to controls, which received only empty capsules. The improvements in symptoms were seen within two weeks and persisted for at least six months, the end-point of the trial. Microscopic analysis of both treated and untreated brain regions clearly showed an increase in the number of dopamine producing neurons in the NTCELL treated subjects compared to controls. In addition, there was no cellular or pathological evidence of inflammation or other adverse event.

Professor Robert Elliott said, "Today we have presented a comprehensive suite of pre-clinical data in small animal and non-human primate studies which show an astonishing recovery of the part of the brain affected in Parkinson's disease, as well as a more than 50% improvement in the devastating movement and neurological symptoms of the disease. We are now compiling an application to New Zealand's medicines safety authority, Medsafe, to start Phase I clinical trials in Parkinson's patients. Pending regulatory authorisation, LCT expects to begin these trials by the end of Q1 2013."

Dr Andrea Grant, Chief Executive Officer of LCT said, "BioPharma Asia is the leading forum through which the most influential decision makers in the Asian and global biopharmaceutical industry forge partnerships. We are delighted to have been invited to present our unprecedented results of NTCELL in Parkinson's as a plenary."

About Living Cell Technologies Limited

Living Cell Technologies (LCT) is an Australasian biotechnology company and world leader in developing cell therapies to treat diseases with high unmet clinical need. To date, the company has taken two therapeutic candidates into clinical development: DIABECELL(R) for the treatment of Type 1 diabetes and NTCELL(R), which is in Phase I clinical trials in New Zealand for the treatment of Parkinson's disease.

Through an innovative joint venture with international pharmaceutical company Otsuka Pharmaceutical Factory (OPF), LCT has secured funding, based on the achievement of clinical milestones, for the clinical development of DIABECELL and the Phase I clinical trials of NTCELL in Parkinson's disease. LCT retains a 50% share of future profits from DIABECELL and NTCELL and a perpetual, exclusive licence to continue to develop products using intellectual property held outside the DOL partnership.

LCT’s unique, proprietary technology, IMMUPEL(TM), allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system, which often have negative side-effects.

LCT is listed on the Australian (ASX:LCT) and US (OTCQX:LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, operations and manufacturing facilities based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter